Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive
to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining oblimersen and irinotecan
in treating patients who have metastatic or recurrent colorectal cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio